Stockscreener 앱 받기
30.55
0.07%
0.02
시간 외 거래:
30.34
-0.21
-0.69%
전일 마감가:
$30.53
열려 있는:
$30.53
하루 거래량:
91,495
Relative Volume:
0.32
시가총액:
$38.54M
수익:
-
순이익/손실:
$-26.82M
주가수익비율:
-2.8683
EPS:
-10.6509
순현금흐름:
$-24.28M
1주 성능:
-2.08%
1개월 성능:
+12.23%
6개월 성능:
+239.44%
1년 성능:
+234.25%
1일 변동 폭
$30.03
$32.14
1주일 범위
$28.51
$33.22
52주 변동 폭
$5.00
$36.76
센세이 바이오테라 Stock (SNSE) Company Profile
명칭
Sensei Biotherapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
30.55 | 38.52M | 0 | -26.82M | -24.28M | -10.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
센세이 바이오테라 Stock (SNSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
센세이 바이오테라 주식(SNSE)의 최신 뉴스
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Anand Kiran Parikh Net Worth (2026) - GuruFocus
Sensei Biotherapeutics announces inducement grants under Nasdaq listing rule - TipRanks
Sensei Biotherapeutics (SNSE) Announces Stock Option Grant to Ne - GuruFocus
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Sensei Biotherapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Sensei Biotherapeutics hire gets option on 166K shares - Stock Titan
Why Sensei Biotherapeutics Inc. stock is favored by pension funds2026 Pullbacks & Reliable Entry Point Trade Alerts - Naître et grandir
Update Recap: How buybacks impact Sensei Biotherapeutics Inc. stock valueCEO Change & Comprehensive Market Scan Insights - Naître et grandir
Published on: 2026-03-07 01:25:22 - Naître et grandir
Can Sensei Biotherapeutics Inc be the next market leaderQuarterly Profit Review & Technical Confirmation Alerts - baoquankhu1.vn
Rate Hike: Is Sensei Biotherapeutics Inc a strong growth stockMarket Activity Recap & Stepwise Trade Execution Plans - baoquankhu1.vn
Fed Meeting: Whats next for CRWD stock2025 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
Trails Edge Capital Partners, LP Acquires Shares in Sensei Bioth - GuruFocus
Revenue Check: Is Sensei Biotherapeutics Inc being accumulated by smart moneyWeekly Gains Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Sensei Biotherapeutics grants stock options to 17 new employees - Investing.com
Trails Edge files 9.9% ownership in Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
SNSE (NASDAQ: SNSE) insider schedules sale of 3,374 shares; prior sale 42,594 - Stock Titan
SNSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sensei Biotherapeutics Acquires Faeth Therapeutics and Raises US$200 Million in Private Placement - Global Legal Chronicle
SNSESensei Biotherapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Sensei Biotherapeutics Merges with Faeth Therapeutics, Secures $200M Funding - National Today
What is Sensei Biotherapeutics Inc. s revenue forecastJuly 2025 Trade Ideas & Precise Buy Zone Tips - mfd.ru
Sensei Biotherapeutics Acquires Faeth Therapeutics - Global Legal Chronicle
Sensei Biotherapeutics (SNSE) COO and director added as SEC insider - Stock Titan
Sensei Biotherapeutics Closes Faeth Acquisition and Financing - The Globe and Mail
Sensei Biotherapeutics Secures Future with Faeth Therapeutics Acquisition and $200M Financing - Beijing Times
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - MSN
Sensei Biotherapeutics Acquires Faeth Therapeutics and Secures $200 Million Funding - El-Balad.com
Sensei Biotherapeutics PIPE in Connection with its Acquisition of Faeth Therapeutics - Leerink Partners
Sensei/Faeth Merger Will Keep Both Firms’ Cancer Pipelines Active - Citeline News & Insights
Merger deal renews Faeth in Sensei; Piktor brightens, stock jumps - BioWorld MedTech
Small Cap Stocks To Add to Your WatchlistFebruary 18th - MarketBeat
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal - Bitget
Why Is Sensei Biotherapeutics Stock Skyrocketing Wednesday?Sensei Biotherapeutics (NASDAQ:SNSE) - Benzinga
Sensei Biotherapeutics (SNSE) Shares Soar After $200M Acquisitio - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance - HIT Consultant
Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug - Fierce Biotech
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider
Sensei Jumps 150% On Faeth Therapeutics Buyout And $200M Financing - Nasdaq
Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition By Investing.com - Investing.com Canada
Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition - Investing.com
SNSE: Acquisition and $200M financing position the combined entity as a leader in multi-node cancer therapies - TradingView
Sensei Biotherapeutics (SNSE) Acquires Faeth Therapeutics to Exp - GuruFocus
SNSE: Acquisition and $200M financing advance a novel cancer therapy toward key clinical milestones - TradingView
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - The Joplin Globe
Form 4: Donenberg Phillip B. reports acquisition/exercise transactions in SNSE - Stock Titan
SNSE Technical Analysis & ETF Price Forecast - Intellectia AI
Sensei Biotherapeutics Expands Board, Adds Finance Expertise - The Globe and Mail
센세이 바이오테라 (SNSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):